MARKET

ORMP

ORMP

Oramed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.30
+0.04
+0.39%
Closed 16:00 05/14 EDT
OPEN
10.87
PREV CLOSE
10.26
HIGH
10.87
LOW
10.04
VOLUME
248.91K
TURNOVER
--
52 WEEK HIGH
12.73
52 WEEK LOW
2.400
MARKET CAP
311.35M
P/E (TTM)
-16.3414
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 3d ago
8-K: ORAMED PHARMACEUTICALS INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 3d ago
BRIEF-Oramed Pharmaceuticals - On May 6, CFO, Treasurer And Secretary Of Co Resigned From His Positions With Co Effective As Of July 5
reuters.com · 3d ago
Oramed Pharma initiated buy at Cantor citing the potential of oral insulin therapy
Late March Oramed Pharmaceuticals ([[ORMP]] -1.2%) surged in reaction to the announcement of the beginning of the second of two simultaneous Phase 3 studies for its oral insulin capsule, ORMD-0801 that targets
Seekingalpha · 04/20 19:59
Canaccord Genuity Starts Oramed Pharmaceuticals at Buy With $27 Price Target
MT Newswires · 04/20 09:55
Is Oramed Pharmaceuticals' (NASDAQ:ORMP) 167% Share Price Increase Well Justified?
Oramed Pharmaceuticals Inc. ( NASDAQ:ORMP ) shareholders might be concerned after seeing the share price drop 14% in...
Simply Wall St. · 04/19 13:56
Diabetic Ketoacidosis Treatment Market Industry Analysis, Market Size, Trends, Share and Forecast 2027
Apr 16, 2021 (Market Insight Reports) -- The report on Diabetic Ketoacidosis Treatment provides the clients with an in-depth analysis of market share, market...
Market Insight Reports · 04/16 13:50
Diabetic Ketoacidosis Market Size, Industry Growth, Sales Revenue, COVID-19 Market Scenario, Opportunity, and Industry Expansion Strategies to 2027
Apr 15, 2021 (Market Insight Reports) -- Technological advancements in diabetic ketoacidosis treatment, significant prevalence of target diseases, and rising...
Market Insight Reports · 04/15 13:51
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ORMP. Analyze the recent business situations of Oramed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ORMP stock price target is 21.17 with a high estimate of 27.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 1.25M
% Owned: 4.14%
Shares Outstanding: 30.23M
TypeInstitutionsShares
Increased
4
16.33K
New
11
76.39K
Decreased
9
249.68K
Sold Out
8
392.42K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.15%
Key Executives
Chairman/Independent Director
Kevin Rakin
Chief Executive Officer/President/Director
Nadav Kidron
Chief Financial Officer/Treasurer/Secretary
Avi Gabay
Chief Financial Officer/Treasurer/Secretary
Avraham Gabay
Chief Operating Officer
Joshua Hexter
Chief Scientific Officer/Director
Miriam Kidron
Independent Director
Aviad Friedman
Independent Director
Xiaoming Gao
Independent Director
Arie Mayer
Independent Director
Leonard Sank
No Data
About ORMP
Oramed Pharmaceuticals Inc. is a pharmaceutical company. It is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Its pipeline products are ORMD-0801 Type 1, ORM-0801 Type 2 and ORMD-0901. Its flagship product, ORMD-0801, is an orally ingestible insulin capsule. It is anticipated for use as a complementary agent to insulin injections in the treatment of Type I diabetes Mellitus (T1DM) and T2Dm disease. This treatment regimen should allow for fewer daily injections and a lower frequency of blood glucose fluctuations in cases of unstable and brittle T1DM. Glucagon-like peptide-1 (GLP-1) is an incretin hormone, which is a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. The Company's other product is ORMD-0901, an orally ingestible GLP-1 capsule.

Webull offers kinds of Oramed Pharmaceuticals, Inc. stock information, including NASDAQ:ORMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ORMP stock methods without spending real money on the virtual paper trading platform.